Genedrive PLC (GB00B1VKB244)

Overview

Genedrive plc operates as a molecular diagnostics company focused on the research, development, and commercialization of point of need diagnostics platforms aimed at infectious diseases, genotyping, pathogen detection, and various other indications. The company, which was initially known as Epistem Holdings Plc, rebranded to Genedrive plc in July 2016. Since its inception in 2000, Genedrive plc has been contributing to the medical, biotechnology, and pharmaceutical sectors, offering innovative diagnostic solutions. Headquartered in Manchester, United Kingdom, the company has established a broad presence, serving clients across the United Kingdom, Europe, the United States, and other international markets.

Products and Services

Genedrive plc has developed and commercialized a range of diagnostic products and services, including:

• Genedrive system: This product is a rapid thermocycler and signal detection system, which functions as a semi-automated system for qualitative in vitro molecular diagnostic tests. It is designed to provide swift and reliable diagnostic results at the point of need.
• Genedrive CYP2C19 ID Kit: A point-of-care test specifically designed for rapid CYP2C19 genotyping. This is especially crucial in time-critical emergency care settings, where quick and informed decision-making can significantly impact patient outcomes.
• Genedrive MT-RNR1-ID Kit: This rapid genetic test is aimed at use in emergency neonatal care settings. It's crafted for specific medical conditions that require immediate diagnosis to guide treatment decisions effectively right from the start.
• Tests for Antibiotic Induced Hearing Loss in neonates: These diagnostic tests are crucial for detecting the risk of hearing loss induced by antibiotics in newborns, allowing for immediate adjustments in treatment plans to prevent potential hearing damage.
• Confirmation of HCV infection: Genedrive's offering includes tests designed for the rapid confirmation of Hepatitis C virus infections prior to the commencement of drug treatment, streamlining the pathway to care.
• Pathogen detection of biological military threats: The company also provides solutions for detecting a range of biological military threats, bolstering defense and preparedness strategies for military and national security organizations.
• Point-of-care COVID-19 detection system: In response to the global pandemic, Genedrive developed a COVID-19 detection system suitable for use in a variety of settings, including healthcare, workplace screening, travel requirements, and for confirming antigen test results.